Skip to content
2000
Volume 20, Issue 5
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

Background

Adverse drug reactions (ADRs) are one of the primary reasons behind poor medication compliance/ adherence in tuberculosis (TB) patients. However, ADR is preventable or manageable through proper screening and patient education.

Objectives

In this study, we aim to find out the prevalence of ADRs, their effect on patient compliance, and the impact of patient counselling on patient compliance in TB Patients.

Material and Methods

About 250 TB patients who were receiving anti-tubercular treatment (ATT) were screened for ADRs. Causality, severity, and preventability assessment of ADRs were done using the Naranjo Algorithm, the Modified Hartwig and Seigel scale, and the Modified Schumock and Thornton scale, respectively. Each patient was telephonically counselled regarding ATT and ADRs associated with it for a period of 2 months to check the impact of counselling on patient compliance using the Morisky-Medication-Taking Adherence Scale.

Results

Out of 250 TB patients, 25.6% of tuberculosis patients developed ADRs. According to causality assessment, 50.79% and 47.61% of the ADRs were probable and possible, respectively. About 48.41% of ADRs were mild, 50.79% of ADRs were moderate, and only 1 (0.79%) of ADR was severe and required intensive care. About 47.62% of ADRs were found to be preventable, 23.81% of ADRs were preventable, and 28.57% of ADRs were non-preventable. A statistically significant improvement was seen in patient medication compliance after counselling (<0.05).

Conclusion

This present study concludes that one-fourth of the TB patients receiving ATT reported ADRs. The majority of the ADRs were mild to moderate and preventable with proper screening and patient education. Patient counselling significantly improved the medication compliance of the patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855327155240819060548
2025-03-04
2025-09-23

  • From This Site

    /content/journals/cdth/10.2174/0115748855327155240819060548
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ImamF. SharmaM. KhayyamK.U. Al-HarbiN.O. RashidM.K. AliM.D. AhmadA. QamarW. Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs.Saudi Pharm. J.202028331632410.1016/j.jsps.2020.01.01132194333
     [Google Scholar]
  2. Tuberculosis.2022Available from: https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis 2022, October 27.
  3. Tuberculosis.2023Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis#:~:text=Worldwide%2C%20TB%20is%20the%2013th,all%20countries%20and%20age%20groups 2023, November 7.
  4. Tuberculosis.2020Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis#:~:text=In%202020%2C%20the%2030%20high,Nigeria%2C%20Bangladesh%20and%20South%20Africa
  5. Treatment of tuberculosis: guidelines. World Health Organization.2010Available from: https://www.who.int/news/item/07-05-2010-treatment-of-tuberculosis-guidelines-for-national-programme
  6. BoomW.H. SchaibleU.E. AchkarJ.M. The knowns and unknowns of latent Mycobacterium tuberculosis infection.J. Clin. Invest.20211313e13622210.1172/JCI13622233529162
     [Google Scholar]
  7. PrasadR. SinghA. GuptaN. Adverse drug reactions in tuberculosis and management.Indian J. Tuberc.201966452053210.1016/j.ijtb.2019.11.00531813444
     [Google Scholar]
  8. KhaitanA. RaiS.K. KrishnanA. GuptaS.K. KantS. KhilnaniG.C. “Better to die than take these medicines”: A community-based qualitative study on the determinants of treatment loss-to-follow-up in tuberculosis patients in district faridabad, Haryana, India.Cureus2022145e2503010.7759/cureus.2503035591891
     [Google Scholar]
  9. SulimanQ. LimP.Y. Risk factors for early TB treatment interruption among newly diagnosed patients in Malaysia.Sci. Rep.202212110.1038/s41598‑021‑04742‑2
     [Google Scholar]
  10. SinghD. SinghV. MandalS.P. DsouzaK. KumarB.R.P. DixitS.R. Drug targets, current and future therapeutics for the treatment of multi drug resistant tuberculosis with their clinical applications: A critical review.Curr. Drug Ther.202419331732610.2174/1574885519666230830125139
     [Google Scholar]
  11. Prevention and management of adverse reactions associated with antitubercular drugs. Indian Council of Medical Research (ICMR), Central TB Division (CTBD)-Director General of Health Services, Government of India.2016Available from: https://www.tbcindia.gov.in/WriteReadData/Prevention%20and%20Management%20of%20Adverse%20Reaction/files/assets/common/downloads/publication.pdf
  12. Monitoring during treatment.Treatment of Tuberculosis: Guidelines.4th edGenevaWorld Health Organization20104
     [Google Scholar]
  13. NaranjoC.A. BustoU. SellersE.M. SandorP. RuizI. RobertsE.A. JanecekE. DomecqC. GreenblattD.J. A method for estimating the probability of adverse drug reactions.Clin. Pharmacol. Ther.198130223924510.1038/clpt.1981.1547249508
     [Google Scholar]
  14. PandeS. Causality or Relatedness assessment in adverse drug reaction and its relevance in dermatology.Indian J. Dermatol.2018631182110.4103/ijd.IJD_579_1729527021
     [Google Scholar]
  15. HartwigS.C. SiegelJ. SchneiderP.J. Preventability and severity assessment in reporting adverse drug reactions.Am. J. Health Syst. Pharm.19924992229223210.1093/ajhp/49.9.22291524068
     [Google Scholar]
  16. SchumockG.T. ThorntonJ.P. Focusing on the preventability of adverse drug reactions.Hosp. Pharm.199227653810118597
     [Google Scholar]
  17. MoriskyD.E. GreenL.W. LevineD.M. Concurrent and predictive validity of a self-reported measure of medication adherence.Med. Care1986241677410.1097/00005650‑198601000‑000073945130
     [Google Scholar]
  18. KohY. YapC.W. LiS.C. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.Int. J. Med. Inform.200877642143010.1016/j.ijmedinf.2007.08.01017921048
     [Google Scholar]
  19. NandaG.S. SinghH. SharmaB. AroraA. Adverse reactions due to directly observed treatment short course therapy: An indian prospective study.IAIM201631612
     [Google Scholar]
  20. AthiraB. ManjuC.S. JyothiE. A study on adverse drug reactions to first-line antitubercular drugs in DOTS therapy.Int J Pharmacol and Clin Sci20154711
     [Google Scholar]
  21. NandyM. NaserS.M. BanuP. BanerjeeA. PaulS. PodderI. MukherjeeM. Adverse drug reaction monitoring through active surveillance of antitubercular therapy in an urban tertiary care center.Community Acquired Infection201632515410.4103/2225‑6482.184913
     [Google Scholar]
  22. SharmaB.S. LodhiN.S. GoswamiR.B. BankeA. Pharmacovigilance study of anti-tubercular drugs in a community healthcare hospital.Adv. Pharm. J.20216410311010.31024/apj.2021.6.4.2
     [Google Scholar]
  23. YeeD. ValiquetteC. PelletierM. ParisienI. RocherI. MenziesD. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.Am. J. Respir. Crit. Care Med.2003167111472147710.1164/rccm.200206‑626OC12569078
     [Google Scholar]
  24. MarraF. MarraC.A. BruchetN. RichardsonK. MoadebiS. ElwoodR.K. FitzgeraldJ.M. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.Int. J. Tuberc. Lung Dis.200711886887517705952
     [Google Scholar]
  25. P vK. PalaianS. OjhaP. P RS. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.Pak. J. Pharm. Sci.2008211515618166520
     [Google Scholar]
  26. HireD.R.C. KaleD.A.S. DakhaleD.G.N. GaikwadD.N.N. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.Mediterr. J. Hematol. Infect. Dis.201461e201406110.4084/mjhid.2014.06125237474
     [Google Scholar]
  27. AmalbaA. BugriA.A. Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana.Pan Afr. Med. J.20213819133995797
     [Google Scholar]
  28. JaiswalS. SharmaH. JoshiU. AgrawalM. SheohareR. Non-adherence to anti-tubercular treatment during COVID-19 pandemic in Raipur district Central India.Indian J. Tuberc.202269455856410.1016/j.ijtb.2021.08.03336460389
     [Google Scholar]
/content/journals/cdth/10.2174/0115748855327155240819060548
Loading
Adverse Drug Reaction of Antitubercular Drugs and Impact of Patient Counselling on Compliance in Tuberculosis Patients: A Prospective Study
Curr Drug Ther 20, 772 (2025); https://doi.org/10.2174/0115748855327155240819060548
/content/journals/cdth/10.2174/0115748855327155240819060548
/content/journals/cdth/10.2174/0115748855327155240819060548
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Adverse drug reaction; anti-tubercular treatment; causality; extra-pulmonary tuberculosis; patient compliance; preventability; severity; tuberculosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test